Lead Product(s): LSALT peptide
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Metablok
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
The Phase II trial is an international, multicenter, randomized, double-blind, placebo-controlled, proof of concept study of LSALT peptide (Metablok) as prevention of organ inflammation known to trigger ARDS and acute kidney injury (AKI) in patients infected with COVID-19.